5. Jiang G, Li RH, Sun C, Liu YQ, Zheng JN. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis. PLoS One. 2014 Dec 11;9(12):e111920.
7. Australian Product Information (PI). Dacarbazine. 2023. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01825-1&d=202005111016933
9. Uchida A, Ohtake H, Suzuki Y, Sato H, Seto Y, Onoue S, Oguchi T. Photochemically stabilized formulation of dacarbazine with reduced production of algogenic photodegradants. Int J Pharm. 2019 Jun 10;564:492-498.
12. Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol. 2007 May;59(6):749-57.
18. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18(2):376‐380.